Madrigal Pharmaceuticals said Monday that its experimental pill significantly reduced liver fat by just under half without any serious safety issues — achieving the goals of a “real life” Phase 3 clinical trial involving patients with the fatty liver disease known as NASH.
With just under 1,000 patients treated for one year, the study’s main goal was to demonstrate that Madrigal’s NASH treatment, called resmetirom, could be administered chronically without causing potentially harmful side effects.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
